Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
- 1 April 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (4) , 942-951
Abstract
The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway. NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases that regulate degradation of a distinct subset of proteins. The more targeted impact of NEDD8-activating enzyme on protein degradation prompted us to study MLN4924, an investigational NEDD8-activating enzyme inhibitor, in preclinical multiple myeloma models. In vitro treatment with MLN4924 led to dose-dependent decrease of viability (EC50 = 25–150 nmol/L) in a panel of human multiple myeloma cell lines. MLN4924 was similarly active against a bortezomib-resistant ANBL-6 subline and its bortezomib-sensitive parental cells. MLN4924 had submicromolar activity (EC50 values + multiple myeloma patient cells and exhibited at least additive effect when combined with dexamethasone, doxorubicin, and bortezomib against MM.1S cells. The bortezomib-induced compensatory upregulation of transcripts for ubiquitin/proteasome was not observed with MLN4924 treatment, suggesting distinct functional roles of NEDD8-activating enzyme versus 20S proteasome. MLN4924 was well tolerated at doses up to 60 mg/kg 2× daily and significantly reduced tumor burden in both a subcutaneous and an orthotopic mouse model of multiple myeloma. These studies provide the framework for the clinical investigation of MLN4924 in multiple myeloma. Mol Cancer Ther; 11(4); 942–51. ©2012 AACR.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphomaBlood, 2010
- The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and TherapyGenes & Cancer, 2010
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemiaBlood, 2010
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityNature Medicine, 2010
- Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of CancerClinical Cancer Research, 2009
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancerNature, 2009
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2006
- Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsCancer Cell, 2004
- Molecular sequelae of proteasome inhibition in human multiple myeloma cellsProceedings of the National Academy of Sciences, 2002
- TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applicationsBlood, 2001